Tuberc Respir Dis.  2002 May;52(5):485-496.

Activation of NF-kappaB in Lung Cancer Cell Lines in Basal and TNF-alpha Stimulated States

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of medicine, Seoul, Korea. ywkim@snu.ac.kr
  • 2Lung Institute Seoul National University College of medicine, Seoul, Korea.

Abstract

BACKGROUND: The NF-kappaB transcription factors control various biological processes including the immune response, acute phase reastion and cell cycle regulation. NF-kappaB complexes are retained in the cytoplasm in the basal state and various stimuli cause a translocation of the NF-kappaB complexes into the nucleus where they bind to the kappaB elements and regulate the transcription of the target genes. Recent reports also suggest that NF-kappaB proteins are involved in oncogenesis, tumor growth and metastasis. High expression of NF-kappaB expression was reported in many cancer cell lines and tissues. The constitutive activation of NF-kappaB was also reported in several cancer cell lines supporting its role in cancer development and survival. The anti-apoptotic action of NF-kappaB is important for cancer survival. NF-kappaB also controls the expression of several proteins that are important for cellular adhesion (ICAM-1, VCAM-1) suggesting a role in cancer metastasis. In lung cancer, high expression levels of the NF-kappaB subunit p50 and c-Rel were reported. In fact, high expression does not mean a high activity, and the activation pattern of NF-kappaB in lung cancer has not been reported.
METHODS
In this study, the NF-kappaB nuclear binding activity in the basal and TNF-alpha stimulated states were examined in various lung cancer cell lines and compared with the normal bronchial epithelial cell line. Twleve lung cancer cell lines including the non-small cell and small cell lung cancer cell lines (A549, NCL-H358, NCI-H441, NCL-H522, NCL-H2009, NCI-H460, NCI-H1229, NCI-H1703, NCL-H157, NCL-H187, NCI-H417, NCI-H526) and BEAS-2B bronchial epithelial cell line were used. To evaluate the NF-kappaB expression amd DNA binding activity, western blot analysis and an electrophoretic mobility shift assay with the nuclear protein extracts.
RESULTS
The basal expressions of the p50 subunits were observed in the BEAS-2B cell line and all lung cancer cell lines except for NCI-H358 and NCI-H460. The expression levels of p65 and p50 were increased 30 minutes after stimulation with TNF- alpha in BEAS-2B and in 10 lung cancer cell lines. In the NCI-H358 and NCI-H460 cell lines, p65 expression was not observed in the basal and stimulated states and the two p50 related protein levels were higher after stimulation with TNF-alpha. These new proteins were smaller than p50 and are thought to be variants of p50. In the basal state, NF-kappaB was nearly activated in the BEAS-2B and all lung cancer cell lines. The DNA binding activity of the NF-kappaB complexes was markedly higher after stimulation with TNF-alpha. In the BEAS-2B and all lung cancer cell lines except for NCI-H358 and NCI-H460, the activated NF-kappaB complex was a p65/p60 heterodimer. In the NCI-H358 and NCI-H460 lung cancer cell lines, the NF-kappaB complex was variant of a p50/p50 homodimer.
CONCLUSION
The NF-kappaB activation pattern in the lung cancer cell lines and the normal bronchial epithelial cell lines was similar except for the activatio of a variant of the p50/p50 homodimer in some lung cancer cell lines.

Keyword

Lung cancer; NF-kappaB; A ctivation; p50; p65

MeSH Terms

Acute-Phase Reaction
Biological Processes
Blotting, Western
Carcinogenesis
Cell Cycle
Cell Line*
Cytoplasm
DNA
Electrophoretic Mobility Shift Assay
Epithelial Cells
Lung Neoplasms*
Lung*
Neoplasm Metastasis
NF-kappa B*
Nuclear Proteins
Small Cell Lung Carcinoma
Transcription Factors
Tumor Necrosis Factor-alpha*
DNA
NF-kappa B
Nuclear Proteins
Transcription Factors
Tumor Necrosis Factor-alpha
Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr